Trials / Completed
CompletedNCT01157377
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-214868 | AGN-214868 injected into the bladder. |
| DRUG | AGN-214868 placebo | AGN-214868 placebo injected into the bladder. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-02-01
- Completion
- 2013-05-01
- First posted
- 2010-07-07
- Last updated
- 2014-03-19
- Results posted
- 2014-03-19
Locations
3 sites across 3 countries: United States, France, Netherlands
Source: ClinicalTrials.gov record NCT01157377. Inclusion in this directory is not an endorsement.